Henry Schein, Inc. $HSIC Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 14.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 104,740 shares of the company’s stock after purchasing an additional 13,441 shares during the period. Envestnet Asset Management Inc. owned 0.09% of Henry Schein worth $6,952,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein in the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter valued at $27,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Henry Schein during the second quarter valued at $43,000. Evelyn Partners Investment Management Services Ltd purchased a new stake in Henry Schein during the 2nd quarter worth about $62,000. Finally, Mather Group LLC. acquired a new position in Henry Schein in the 3rd quarter valued at about $71,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on HSIC. Mizuho set a $81.00 price target on shares of Henry Schein and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Wells Fargo & Company raised their target price on shares of Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Barrington Research set a $79.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Barclays assumed coverage on Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target for the company. Finally, Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $76.42.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $79.57 on Friday. The company has a market cap of $9.37 billion, a P/E ratio of 25.18, a P/E/G ratio of 2.28 and a beta of 0.88. The firm’s 50 day moving average is $77.37 and its two-hundred day moving average is $71.59. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.80. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.